OSIR
Osiris Therapeutics Inc.
Healthcare
12/16/2013
Presented
| Date | 12/11/2013 |
| Price | $14.47 |
| Market Cap | $0.49B |
| Ent Value | $0.46B |
| P/E Ratio | 12.89x |
| Book Value | $2.39 |
| Div Yield | N/A |
| Shares O/S | 33.85M |
| Ave Daily Vol | 370,000 |
| Short Int | 7.89% |
Current
| Price | $18.99 |
| Market Cap | $0.66B |
| Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Biosurgery and Therapeutics. The Biosurgery segment develops, manufactures, and distributes biologic products for orthopedic, wound healing, and surgical procedures by harnessing the ability of cells and novel constructs for the body's natural healing. It offers Grafix for application to acute and chronic wounds, including diabetic foot ulcers and burns; and Ovation for use in surgical applications. This segment markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. The Therapeutics segment develops and markets products to treat medical conditions in the inflammatory and cardiovascular disease areas. It offers Prochymal for the treatment of refractory acute graft versus host disease in children. This segment also develops biologic stem cell drug candidates, such as Prochymal that is in clinical trials for various indications, including acute graft versus host disease in pediatric and adult patients, Crohn's disease, and acute myocardial infarction; and Chondrogen for osteoarthritis and cartilage protection. The company has a collaborative agreement with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland. |
Highlights
The wound care market is highly competitive, and the Centers for Medicare and Medicaid Services (CMS) recently announced a proposal to switch reimbursement for wound care treatments to a bundled payment model from fee-for-service. The presenter is short shares of Osiris (OSIR) because he expects the payment change to have a materially negative impact on sales of Grafix (the company’s lead product), a cellular matrix that competes with Shire's Dermagraft, Organogenesis' Apligraf, Smith & Nephew’s Regranex, and others.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.